
First-in-class non-dopamine Parkinson’s therapy enters Phase II
Cerevance has dosed the first patient in its ASCEND Phase II study to assess the efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease. In February 2023 the company expanded its Series B funding round, raising a total of $116 million. … Read More

